{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:26:49Z","timestamp":1790468809077,"version":"4.1.0"},"reference-count":30,"publisher":"Society of Nuclear Medicine","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.2967\/jnumed.116.181347","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:40:18Z","timestamp":1502412018000},"page":"1539-1544","source":"Crossref","is-referenced-by-count":30,"title":["<sup>18<\/sup>F-FDG PET\/CT in Lymphoma: Has Imaging-Directed Personalized Medicine Become a Reality?"],"prefix":"10.2967","volume":"58","author":[{"given":"Sally F.","family":"Barrington","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2017,8,10]]},"reference":[{"key":"2021051712110969000_58.10.1539.1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.5229"},{"key":"2021051712110969000_58.10.1539.2","doi-asserted-by":"crossref","unstructured":"Johnson PW . Response-adapted frontline therapy for Hodgkin lymphoma: are we there yet? Hematology Am Soc Hematol Educ Program. 2016:316\u2013322.","DOI":"10.1182\/asheducation-2016.1.316"},{"key":"2021051712110969000_58.10.1539.3","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2961-x"},{"key":"2021051712110969000_58.10.1539.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"2021051712110969000_58.10.1539.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408648"},{"key":"2021051712110969000_58.10.1539.6","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol."},{"key":"2021051712110969000_58.10.1539.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510093"},{"key":"2021051712110969000_58.10.1539.8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/hon.2437_18","article-title":"Can baseline PET-CT features predict outcomes in advanced Hodgkin lymphoma? A prospective evaluation of UK patients in the RATHL trial (CRUK\/07\/033)","volume":"35","author":"Pike","year":"2017","journal-title":"Hematol Oncol."},{"key":"2021051712110969000_58.10.1539.9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-679407"},{"key":"2021051712110969000_58.10.1539.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61940-5"},{"key":"2021051712110969000_58.10.1539.11","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood.V126.23.577.577","article-title":"Randomized phase III study comparing an early PET driven treatment de-escalation to a not PET-monitored strategy in patients with advanced stage Hodgkin lymphoma: interim analysis of the AHL2011 LYSA study","volume":"126","author":"Casasnovas","year":"2015","journal-title":"Blood."},{"key":"2021051712110969000_58.10.1539.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.0699"},{"key":"2021051712110969000_58.10.1539.13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.1119"},{"key":"2021051712110969000_58.10.1539.14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.6525"},{"key":"2021051712110969000_58.10.1539.15","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.110890"},{"key":"2021051712110969000_58.10.1539.16","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S1470-2045(17)30103-1","article-title":"Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin\u2019s lymphoma treated with BEACOPP escalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin study group","volume":"18","author":"Borchmann","year":"2017","journal-title":"Lancet Oncol."},{"key":"2021051712110969000_58.10.1539.17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood.V124.21.391.391","article-title":"Positron emission tomography (PET) guided therapy of aggressive lymphomas: a randomized controlled trial comparing different treatment approaches based on interim PET results (PETAL trial) [abstract]","volume":"124","author":"Duehrsen","year":"2014","journal-title":"Blood."},{"key":"2021051712110969000_58.10.1539.18","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/blood.V124.21.392.392","article-title":"Phase 2 trial of interim PET scan-tailored therapy in patients with advanced stage diffuse large B-cell lymphoma (DLBCL) in British Columbia (BC) [abstract]","volume":"124","author":"Sehn","year":"2014","journal-title":"Blood."},{"key":"2021051712110969000_58.10.1539.19","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.154039"},{"key":"2021051712110969000_58.10.1539.20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/hon.2437_119","article-title":"Radiotherapy to bulky disease PET-negative after immunochemotherapy can be spared in elderly DLBCL patients: results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL>60 study of the DSHNHL [abstract]","volume":"35","author":"Pfreundschuh","year":"2017","journal-title":"Hematol Oncol."},{"key":"2021051712110969000_58.10.1539.21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.7524"},{"key":"2021051712110969000_58.10.1539.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214561"},{"key":"2021051712110969000_58.10.1539.23","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(14)70008-0"},{"key":"2021051712110969000_58.10.1539.24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"2021051712110969000_58.10.1539.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"2021051712110969000_58.10.1539.26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9789"},{"key":"2021051712110969000_58.10.1539.27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1624"},{"key":"2021051712110969000_58.10.1539.28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.0391"},{"key":"2021051712110969000_58.10.1539.29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718528"},{"key":"2021051712110969000_58.10.1539.30","doi-asserted-by":"crossref","unstructured":"Dercle L Seban RD Lazarovici J . 18F-FDG PET and CT-scan detect new imaging patterns of response and progression in patients with Hodgkin lymphoma treated by anti-PD1 immune checkpoint inhibitor. J Nucl Med. June 8, 2017 [Epub ahead of print].","DOI":"10.2967\/jnumed.117.193011"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.116.181347","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T20:21:30Z","timestamp":1621282890000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.116.181347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,10]]},"references-count":30,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,10,2]]},"published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.2967\/jnumed.116.181347"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.116.181347","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,10]]}}}